Longevity-focused healthtech startup Biopeak has raised $2.7 million in a follow-on funding spherical led by NKSquared, the enterprise capital agency of Zerodha co-founder Nikhil Kamath.

That is Kamath’s second funding within the startup after placing in $1.43 million in August 2024.

The startup will use the contemporary funds to scale its operations, together with opening a brand new flagship clinic in Bengaluru, increasing its staff, and strengthening its specialist clinics and diagnostics. It additionally plans to speculate extra in its proprietary AI instruments, analysis infrastructure, and medical programmes.

Based by Rishi Pardal and Shiva Subramanian, Biopeak focuses on enhancing healthspan by a longevity-led strategy. It combines mobile and molecular diagnostics, superior imaging, and AI-driven insights to create personalised well being plans.

The startup describes its mannequin as a “household well being workplace” strategy that appears at long-term well being and prevention, not simply therapy. Biopeak’s know-how profiles greater than 130 biomarkers utilizing blood exams, genetic and epigenetic evaluation, microbiome mapping, hormonal evaluation, salivary cortisol rhythms, and whole-exome practical genomics. These are paired with high-resolution imaging resembling MRI, CT, DXA, ECHO, and carotid IMT.

The platform is designed to detect well being dangers early, observe modifications over time, and counsel focused interventions associated to vitamin, sleep, stress, and total life-style.

The Bengaluru-based startup claims that it really works with establishments like IISc and Longevity India to higher adapt well being knowledge to South Asian genetics, atmosphere, and life-style. This helps enhance the relevance and accuracy of its care. Biopeak launched its first clinic in Bengaluru final 12 months and plans to open one other clinic within the metropolis quickly.